




NNHLA

National Non-Hodgkin
Lymphoma Audit

State of the Nation Report 2024

Summary of results for people diagnosed with Non-Hodgkin Lymphoma (NHL) in England (2020-2021) and Wales (2022).

Data completeness



Diagnosis and staging

Diagnoses per year

England
14,099 diagnosed in 2020
14,973 diagnosed in 2021

Wales
619 diagnosed in 2022

Grade of lymphoma

England 2020-2021
high-grade 51%, low-grade 47%, not classified 1%

Wales 2022
high-grade 49%, low-grade 51%, not classified 0.2%

MDT discussion within 4 weeks of diagnosis, where recorded

England 2020 - 69%,
(high-grade 74.5%, low-grade 61.8%)

England 2021 - 63.5%,
(high-grade 68.6%, low-grade 57.3%)

No data on MDT discussion was provided for Wales



69
years

Mean age at diagnosis for both England & Wales

Clinical Nurse Specialist (CNS) seen, where recorded

82% of people diagnosed with NHL seen by a CNS in **England** (2020 & 2021) and 96% in **Wales**.
CNS information was recorded in only 37% of people diagnosed with NHL in **England** and 69% in **Wales**.

Treatment

Chemotherapy treatment

Percentage of people diagnosed with high grade lymphoma, who received chemotherapy within 62 days of referral.

England 2020



England 2021



Wales 2022



Radiotherapy treatment

Percentage of people diagnosed with high-grade lymphoma, who received radiotherapy within 8 weeks of end of first line chemotherapy.

England 2020



England 2021



End date for 1st line chemotherapy was not provided for Wales so this indicator could not be measured.

Survival

One-year survival outcomes

